Atlas Trials

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

Clinical trial NCT03512405 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03512405
Sponsor
City of Hope Medical Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
CD19 PositivePhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
Start date
2019-08-02
Primary completion
2025-11-11
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.